Information  X 
Enter a valid email address

SkinBioTherapeutics (SBTX)

  Print   

Monday 15 March, 2021

SkinBioTherapeutics

Exercise of Warrant

RNS Number : 2978S
SkinBioTherapeutics PLC
15 March 2021
 

SkinBioTherapeutics plc

 

Exercise of Warrant

 

Manchester, UK - 15 March 2021 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") a life sciences company focused on skin health, announces that it has received notification for the exercise of warrant over 890,314 ordinary shares in the Company at an exercise price of 9 pence per share providing the Company with proceeds of £80,128.26 ("Warrant Exercise").

 

Application will be made to the London Stock Exchange to admit the 890,314 new ordinary shares resulting from the Warrant Exercise to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 19 March 2021 ("Admission"). The new ordinary shares will rank pari passu with the existing ordinary shares.

 

For the purpose of the Disclosure and Transparency Rules, following Admission the enlarged issued share capital of the Company will comprise 156,780,236 ordinary shares of 1 pence each. The Company does not hold any shares in treasury. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

 

 

-Ends-

 

 For more information, please contact:

SkinBioTherapeutics plc
Stuart J . Ashman, CEO
Doug Quinn, CFO

Tel: +44 (0) 161 468 2760



Cenkos Securities Plc  (Nominated Adviser & Broker)
Giles Balleny, Max Gould (Corporate Finance)
Michael Johnson (Sales)

Tel: +44 (0) 20 7397 8900



Instinctif Partners
Melanie Toyne-Sewell / Phillip Marriage / Nathan Billis

Tel: +44 (0) 20 7457 2020
[email protected]

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEGPUUCWUPGGWA

a d v e r t i s e m e n t